Anmelden Kostenlos registrieren

Novabay Pharmaceuticals Inc Marktkapitalisierung

Was ist das Marktkapitalisierung von Novabay Pharmaceuticals Inc?

Marktkapitalisierung von Novabay Pharmaceuticals Inc ist $3.25M

Was ist die Definition von Marktkapitalisierung?



Die Marktkapitalisierung ist der Marktwert zu einem Zeitpunkt, zu dem die Aktien eines börsennotierten Unternehmens im Umlauf sind, und ist gleich dem Aktienkurs zu diesem Zeitpunkt multipliziert mit der Anzahl der im Umlauf befindlichen Aktien .

As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.

Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.

The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.

Marktkapitalisierung von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Novabay Pharmaceuticals Inc

Was macht Novabay Pharmaceuticals Inc?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Unternehmen mit marktkapitalisierung ähnlich Novabay Pharmaceuticals Inc